Drugs / Personalized polyepitope DNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02348320 | Jun 2015 → Mar 2020 | triple-negative breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized polyepitope DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02348320 ↗ |
| Modality | Vaccine | “personalized polyepitope DNA vaccine strategy” NCT02348320 ↗ |
| Route | Intramuscular | “Each DNA vaccination with be 4 mg vaccine administered intramuscularly” NCT02348320 ↗ |